Lindbrook Capital LLC Has $36,000 Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Lindbrook Capital LLC increased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 183.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,036 shares of the company’s stock after purchasing an additional 671 shares during the period. Lindbrook Capital LLC’s holdings in Ionis Pharmaceuticals were worth $36,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IONS. Capital Performance Advisors LLP acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $40,000. Prospera Private Wealth LLC acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $42,000. Itau Unibanco Holding S.A. lifted its position in shares of Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after purchasing an additional 314 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $51,000. Finally, Quest Partners LLC lifted its position in shares of Ionis Pharmaceuticals by 94.8% during the 3rd quarter. Quest Partners LLC now owns 2,674 shares of the company’s stock worth $107,000 after purchasing an additional 1,301 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IONS. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Piper Sandler lowered their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $36.22 per share, for a total transaction of $181,100.00. Following the transaction, the director now directly owns 35,219 shares in the company, valued at approximately $1,275,632.18. The trade was a 16.55 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Patrick R. O’neil sold 6,165 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares in the company, valued at approximately $1,816,632.24. This trade represents a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,816 shares of company stock worth $3,603,914 in the last three months. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Trading Down 1.7 %

IONS stock opened at $33.81 on Friday. Ionis Pharmaceuticals, Inc. has a 1-year low of $30.23 and a 1-year high of $52.34. The firm has a market cap of $5.37 billion, a P/E ratio of -11.12 and a beta of 0.28. The business’s 50 day moving average is $32.91 and its 200-day moving average is $37.30. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company’s revenue was down 30.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 EPS. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.